EPIX Pharmaceuticals News
Most Popular EPIX Pharmaceuticals Story
Glaxo forges $2.1B deal for HuMax-CD20
Denmark's Genmab will gain up to $2.1 billion in a licensing deal with GlaxoSmithKline for the HuMax-CD20 antibody for leukemia, far outstripping the numbers predicted by analysts. Genmab will get $102 million up front, a 10 percent equity investment worth $357 million and up to $1.6 billion in milestone payments. The therapy is in a late-stage trial for chronic lymphocytic leukemia and non-Hodkin's lymphoma and in mid-stage trials for rheumatoid arthritis and new cases of lymphocytic …
Read more...Latest Headlines
- October 28, 2009
- July 21, 2009
- April 7, 2009
- March 26, 2009
- December 23, 2008
- October 23, 2008
- September 4, 2008
- June 4, 2008
- May 5, 2008
- April 14, 2008
- April 7, 2008
- March 20, 2008
- December 18, 2007
- August 7, 2007
- December 20, 2006
- December 18, 2006
- December 13, 2006
- December 11, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
